A new phase 1 trial demonstrates the safety and effectiveness of personalized neoantigen DNA vaccines, showing promising ...

Highly effective treatments for HIV keep people healthy, but we do not yet have a safe and scalable way to completely rid the ...

Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer based on its unique Mimicry platform, will be holding a webinar to run through new clinical data from the ...

In the urology space, initial clinical trials of ANKTIVA are being designed for high-risk prostate cancer," said Dr. Patrick ...

Both published and newer data suggests that DNase I impedes neutrophil tumor infiltration, promotes CD4 and CD8 T cell infiltration, and enhances intratumoral T cell activation. DNase I plus -CTLA-4 ...

Background Peritoneal metastasis is the most common metastasis pattern of gastric cancer. Patients with gastric cancer ...

Equities researchers at StockNews.com began coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Free Report) in a note issued to investors on Sunday. The brokerage set a “sell” rating on the ...

including CD4/CD8 T cells, regulatory T cells, NK cells, and innate immune cells - Applications to a growing list of autoimmune conditions and cancer types - Effects and responses in treated patients ...

“The impaired numbers of CD3 + T cell may contribute to a weakened anti-tumor response, potentially leading to a poorer prognosis ... The number of IgG, B-lymphocytes, CD4/CD8, CD4 + T-lymphocytes, ...

Nov. 6, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, ...